Literature DB >> 32078140

Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features.

Nicola Lanzarone1, Francesco Gentili2, Valerio Alonzi1, Laura Bergantini1, Miriana d'Alessandro1, Paola Rottoli1, Rosa Metella Refini1, Maria Pieroni1, Lucia Vietri1, Francesco Bianchi1, Maria Antonietta Mazzei3, Luca Volterrani, Anna Perrone1, Paolo Cameli1, Elena Bargagli4, Piersante Sestini1.   

Abstract

Chronic hypersensitivity pneumonitis (cHP) is a fibrotic interstitial lung disease (ILD) resulting from inhalation of different organic substances and chemical compounds determining an inflammatory and immunological response in sensitized individuals. KL-6, a human mucin protein expressed by type 2 pneumocytes, has been proposed as a prognostic biomarker of cHP. Assessment of usefulness KL-6 in ILD has been investigated primarily in Asiatic population. The aim of this study was to evaluate clinical utility of KL-6 in serum and bronchoalveolar lavage (BAL). In this study, we retrospectively analysed clinical, radiological and immunological data of a cohort of 42 patients affected by cHP: KL-6 concentrations were collected from serum and BAL. KL-6 clinical value was assessed through the analysis of association between KL-6 concentrations and clinical, functional, immunological and radiological features. KL-6 serum concentration results increased in 28/34 patients (82%). A positive direct correlation was observed between KL-6 concentrations in BAL and serum (r = 0.62, p < 0.05). In our study population we found that patients with extensive presence of ground glass opacities and centrilobular nodules at high-resolution computed tomography (HRCT) showed the highest concentrations of KL-6 in BAL and a predominantly CD3+ CD8+ BAL lymphocytosis. BAL lymphocytosis and KL-6 concentrations showed a direct correlation. BAL KL-6, a result of alveolar damage, caused in cHP by CD3+ CD8+ mediated flogosis and suggested by radiological evidence of ground-glass opacities and centrilobular nodules, can be considered a useful biomarker to assess, along with BAL cellular analysis and HRCT findings, disease activity.

Entities:  

Keywords:  Biomarker; Bronchoalveolar lavage; Chronic hypersensitivity pneumonitis; KL-6

Mesh:

Substances:

Year:  2020        PMID: 32078140     DOI: 10.1007/s11739-020-02281-8

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  6 in total

1.  Serum KL-6 concentrations as a novel biomarker of severe COVID-19.

Authors:  Miriana d'Alessandro; Paolo Cameli; Rosa Metella Refini; Laura Bergantini; Valerio Alonzi; Nicola Lanzarone; David Bennett; Giuseppe Domenico Rana; Francesca Montagnani; Sabino Scolletta; Federico Franchi; Bruno Frediani; Serafina Valente; Maria Antonietta Mazzei; Francesco Bonella; Elena Bargagli
Journal:  J Med Virol       Date:  2020-06-09       Impact factor: 2.327

2.  Propionibacterium acnes-associated sarcoidosis complicated by acute bird-related hypersensitivity pneumonitis.

Authors:  Michiru Sawahata; Noritaka Sakamoto; Hideaki Yamasawa; Yuki Iijima; Hirotoshi Kawata; Tetsuo Yamaguchi; Keisuke Uchida; Yoshinobu Eishi; Masashi Bando; Koichi Hagiwara
Journal:  BMC Pulm Med       Date:  2020-11-07       Impact factor: 3.317

3.  Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy.

Authors:  Miriana d'Alessandro; Laura Bergantini; Paolo Cameli; Maria Pieroni; Rosa Metella Refini; Piersante Sestini; Elena Bargagli
Journal:  Cancers (Basel)       Date:  2021-02-09       Impact factor: 6.639

4.  Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II.

Authors:  Miriana d'Alessandro; Laura Bergantini; Dalila Cavallaro; Sara Gangi; Paolo Cameli; Edoardo Conticini; Bruno Frediani; Francesco Dotta; Elena Bargagli
Journal:  Int J Environ Res Public Health       Date:  2022-02-15       Impact factor: 3.390

5.  Utility of serological biomarker' panels for diagnostic accuracy of interstitial lung diseases.

Authors:  Laura Bergantini; Miriana d'Alessandro; Lucia Vietri; Giuseppe Domenico Rana; Paolo Cameli; Silvia Acerra; Piersante Sestini; Elena Bargagli
Journal:  Immunol Res       Date:  2020-10-22       Impact factor: 2.829

Review 6.  Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis.

Authors:  Elena Bargagli; Rosa Metella Refini; Miriana d'Alessandro; Laura Bergantini; Paolo Cameli; Lorenza Vantaggiato; Luca Bini; Claudia Landi
Journal:  Int J Mol Sci       Date:  2020-08-07       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.